For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
This is a study of INCB054329 given to patients with advanced malignancies that will be conducted in three treatment groups. Each treatment group will have two parts; a dose escalation (Part 1) and an expansion (Part 2).
Fri, 05/01/2015 to Sun, 10/01/2017
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: INCB054329 Monotherapy Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in three treatment groups, with subsequent cohort escalations in the three treatment groups based on protocol-specific criteria